Last updated on August 2018

Dosing Requirements of Astagraf XL in African American Kidney Transplant Recipients


Brief description of study

Compare the difference in dose-normalized trough and total daily dose necessary to reach the steady state therapeutic goal after conversion from tacrolimus IR to Astagraf XL in African American kidney transplant recipients.

Detailed Study Description

The purpose of this study is to compare the difference in medication dosage and total daily dose necessary of Astagraf XL in order to reach therapy goal, when taken with other medications that are routinely used for kidney transplantation, which may stop the development of a substance that can cause long-term damage to the transplanted kidney. African American kidney transplant patients aged 18 and above who are underwent a kidney transplant are eligible to participate. The duration of the study is 3 months.

Clinical Study Identifier: NCT02953873

Contact Investigators or Research Sites near you

Start Over

James Fleming, PharmD

Medical University of South Carolina
Charleston, SC United States
  Connect »